RxDoctor Payments DataLook up a doctor →

Rahul Sharma, MD

Interventional Cardiology · Stanford, CANPI 1548735509

Payments from drug & device makers

$6,584,762in general payments, 2019–2025

Across 2,050 payments — averaging $3212.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$5.3M
  • Boston Scientific$546K
  • Abbott$280K
  • Cathworks, Inc.$257K
  • Siemens Medical Solutions USA, Inc.$44K
  • Shockwave Medical, Inc$40K
  • plus $85K from 21 others
$4,950in research payments, 2019–2025

Across 1 payment — averaging $4950.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,584,762 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$281,047
Medicare patients
428
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →